September 14, 2017 / 12:14 PM / 10 days ago

BRIEF-Halozyme licenses new Enhanze target for $30 mln upfront payment

Sept 14 (Reuters) - Halozyme Therapeutics Inc:

* Halozyme licenses new enhanze target for $30 million upfront payment, future milestones and royalties

* Halozyme therapeutics-co will receive initial $30 million with potential to earn additional payments of up to $160 million, subject to certain milestones​

* Halozyme therapeutics-licensed its enhanze drug-delivery technology to roche for exclusive development of an undisclosed therapeutic target Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below